🇺🇸 FDA
Pipeline program

Pozelimab + Cemdisiran

R3918-MG-2018

Phase 3 small_molecule active

Quick answer

Pozelimab + Cemdisiran for Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Generalized Myasthenia Gravis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials